Carregant...
Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
Background: Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII (FVIII). FVIII maintains bleeding homeostasis within the body through its downstream effects on the intrinsic clotting cascade. The extent of the disease – mild, moderate or severe – depends on the amount o...
Guardat en:
| Publicat a: | J Drug Assess |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764360/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658327 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|